A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer
Trial status:Study Complete
Trial ID:
NT-002; KEYNOTE: MK-3475-779
NCT ID:
EudraCT ID:
N/A
EU Trial (CTIS) Number:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech US Inc.
Study Complete
Trial Details
The purpose of this study is to find out if treatment with NEO-PV-01 in combination with pembrolizumab and chemotherapy (pembrolizumab/chemotherapy) is safe and useful for patients with lung cancer. The study also will assess if the NEO-PV-01 vaccine, when given together with pembrolizumab and chemotherapy, can improve your response compared with pembrolizumab and chemotherapy treatment alone. All eligible patients will receive NEO-PV-01 + Adjuvant, pembrolizumab and chemotherapy while on this trial.
Medical Condition
Trial Drug
See more
Phase
Phase 1
Type
Interventional
Estimated Enrolment
38
Estimated Trial Date
May 2018 - Oct 2019
Trial Participant Requirements
Age
18+ years
Sex
Female & Male
Healthy Volunteers
No
Trial Locations
Location
Status
Location
University of California - Los Angeles
Santa Monica, California, United States, 90404
Status
Location
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Status
Location
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Status
Location
Washington University in St. Louis
Saint Louis, Missouri, United States, 63130
Status
Location
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Status